Avita Medical says PermeaDerm trial shows 70% cost advantage over allograft with comparable outcomes

Reuters2026/08/18 11:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Avita Medical disclosed positive results from the PermeaDerm-I randomized study in burn care.
Findings were scheduled for review in a Key Opinion Leader webinar at 4:30 p.m. ET on Aug. 18, 2026.
PermeaDerm showed comparable patient outcomes versus cadaveric allograft in temporary wound coverage.
Product economics favored PermeaDerm, positioning it as a lower-cost alternative for hospitals.
Workflow benefits improved versus allograft, supporting an off-the-shelf option with fewer preparation and logistics steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avita Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180745PRIMZONEFULLFEED9811808) on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Avita Medical says PermeaDerm trial shows 70% cost advantage over allograft with comparable outcomes

You may also like

Crypto prices